In June 2023, iruplinalkib (WX-0593) as the class 1 innovative drug was approved for the treatment of ALK-positive crizotinib-resistant advanced NSCLC patients (aged ≥18 years) in China based on the INTELLECT study (ClinicalTrials.gov NCT04641754) (17) and has been included in the updated National Reimbursement Drug List (NRDL, 2023). Here, ALK is linked to non-small cell lung carcinoma.